PO.TB05.02 · 肿瘤生物学

化疗和小分子抑制剂对儿童骨肉瘤3D微环境影响的建模

Modeling the impact of chemotherapy and small molecule inhibitors on the 3D microenvironment of pediatric bone sarcomas

海报缩略图:化疗和小分子抑制剂对儿童骨肉瘤3D微环境影响的建模
编号 6167 展板 3 时间 4/21 02:00–05:00 区域 Section 30 主讲 Allison Reno, BS;PhD
分会场 Pediatric Cancer Models
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Allison Haley Reno1, Joshua Kelley2, Reid Barker3, Jamie Silverman3, Jack Hyland3, Cameron Bumbleburg4, Elizabeth Maahs3, Anna Tingler4, Denis C. Guttridge4, Melinda A. Engevik4, Yongren Wu2, Casey Langdon4

1Pediatrics, The Medical University of South Carolina, Charleston, SC,2Clemson-MUSC Bioengineering, Clemson University, Charleston, SC,3Biology, The College Of Charleston, Charleston, SC,4Medical University of South Carolina, Charleston, SC

摘要 Abstract

中文摘要
儿童肉瘤的主要类型之一是原发性骨肉瘤(PBS),即肉瘤最初发生于骨基质。PBS包括骨肉瘤和尤因肉瘤,二者主要见于儿童人群。骨肉瘤的治疗通常包括截肢或保肢手术,并配合术前和术后化疗,这两者对青少年而言都是重大手术。这些手术可显著限制其长期活动能力,改变其生活质量。这些肉瘤产生类骨质和一种多孔的、矿化的基质,类似于天然骨组织的基质。在本工作中,我们通过创建定制水凝胶材料以匹配骨肉瘤(如骨肉瘤和尤因肉瘤)的ECM特性,设计了儿童肉瘤3D细胞培养模型。我们使用纳米级力学生物学分析来评估纳米级应力、应变、压缩和杨氏模量,以匹配天然骨肉瘤ECM的力学特性,从而精细调整了该材料的组成。我们已在这种材料中培养类器官,利用成像来追踪和定量3D培养肿瘤模型对ECM的重塑。与文献所见一致,我们发现随着肿瘤增殖和进展,胶原增加、胶原重塑导致力学刚度增加,整体ECM刚度增加,从而形成一个更致密、力学上更硬的肿瘤。我们假设化疗药物和小分子抑制剂或许能够削弱我们3D细胞培养模型中所见的致密肿瘤形成和ECM重塑,因为这些药物穿透水凝胶后可诱导细胞凋亡,并导致ECM成分和细胞-基质结合的减少。AKT和蛋白酶体抑制剂均可阻断与I型、III型和IV型胶原相关的通路,这些胶原通过pERK和PI3K/AKT通路驱动肿瘤进展。目标是在我们的肉瘤3D细胞培养模型上检测这些靶向疗法,以观察它们是否会减缓或抑制胶原在驱动儿童实体瘤(其中胶原起着如此重要作用)肿瘤生长和进展中的作用。此外,在诸如尤因肉瘤等免疫“冷”肿瘤中,胶原作为一种重要的免疫抑制信号分子发挥作用,因此抑制胶原信号有助于通过消除胶原在维持免疫“冷”肿瘤中的作用,将尤因肉瘤和其他儿童肉瘤转变为更加免疫“热”的肿瘤。我们预期我们新型的3D培养模型能够模拟肿瘤、微环境和治疗反应之间的复杂关系。
查看英文原文 English abstract
One of the main types of pediatric sarcomas is primary bone sarcoma (PBS) where the sarcoma initially occurs in the bone matrix. PBS includes osteosarcoma and Ewing sarcoma, both of which are primarily seen in pediatric populations. Treatment for osteosarcoma often includes amputation or limb salvaging surgery, along with pre- and post-operative chemotherapy, both of which are significant surgeries for adolescents. These surgeries can significantly limit their long-term mobility, altering their quality of life. These sarcomas produce osteoid and a porous, mineralized matrix like that of native bone tissue. In this work, we have designed pediatric sarcoma 3D cell culture models by creating custom hydrogel materials to match the ECM properties of bone sarcomas such as osteosarcoma and Ewing sarcoma. We refined the composition of this material using nanoscale mechanobiology analysis to assess the nanoscale stress, strain, compression, and Young's modulus to match the mechanical properties of the native bone sarcoma ECM. We have cultured organoids in this material using imaging to track and quantify the ECM remodeling by the 3D culture tumor model. Like what is seen in literature we have found that with tumor proliferation and progression comes increased collagen, collagen remodeling for increased mechanical stiffness, and overall ECM stiffness increased to create a denser, mechanically stiffer tumor. We hypothesize that chemotherapies and small molecule inhibitors may be able to weaken the dense tumor formation and ECM remodeling seen in our 3D cell culture models as the drugs penetrate through the hydrogel induce apoptosis in the cells and lead to a decrease in ECM components and cell-matrix bonding. Both AKT and proteasome inhibitors block the pathways associated with collagen type I, III, and IV driving tumor progression through the pERK and PI3K/AKT pathways. The goal is to test these targeted therapies on our sarcoma 3D cell culture models to see if they would then slow or inhibit the effects of collagen on driving tumor growth and progression in pediatric solid tumors where collagen plays such a vital role. Additionally, in immune “cold” tumors such as Ewing sarcoma collagen functions as an important immunosuppressive signaling molecule so inhibiting collagen in signaling helps to turn Ewing sarcoma and other pediatric sarcomas into more immune “hot” tumors by taking away the role collagen plays in keeping this an immune “cold” tumor. We anticipate our novel 3D culture models can model the complex relationships between tumor, microenvironment, and therapeutic response.
利益披露 Disclosure
A. H. Reno, None.. J. Kelley, None.. R. Barker, None.. J. Silverman, None.. J. Hyland, None.. E. Maahs, None.. Y. Wu, None.

← 返回 AACR 2026 检索